A new class of epilepsy drugs is reaching patients with rare genetic conditions, and the results are striking. Data published on March 5, 2026, in The New England Journal of Medicine showed that zorevunersen, a treatment developed by Stoke Therapeutics and Biogen for Dravet syndrome, reduced convulsive seizures by up to 91 percent in children who had previously experienced an average of 17 seizures per month. This represents the first evidence of genuine disease modification in Dravet syndrome, not merely symptom suppression, but a treatment that addresses the underlying genetic defect. For families who have spent years managing a condition with limited options, this is a turning point.
Zorevunersen is not the only breakthrough. Praxis Precision Medicines has submitted a New Drug Application to the FDA for relutrigine, targeting SCN2A- and SCN8A-related developmental and epileptic encephalopathies, and the already-approved ganaxolone (marketed as Ztalmy) is available for CDKL5 deficiency disorder. Together, these developments signal a shift in how medicine approaches rare genetic epilepsies, moving from broad-spectrum seizure control toward precision therapies tailored to specific mutations. This article covers how these drugs work, what the clinical data actually shows, who stands to benefit, and what limitations families and clinicians should keep in mind.
Table of Contents
- What Makes These Epilepsy Drug Approvals a Breakthrough for Patients With Rare Genetic Conditions?
- How Zorevunersen Works and What the Trial Data Reveals
- Relutrigine and the Expanding Landscape of Precision Epilepsy Treatments
- Ztalmy for CDKL5 Deficiency Disorder — What Families Should Know
- Challenges and Limitations in Rare Genetic Epilepsy Treatment
- The Role of Genetic Testing in Unlocking Precision Epilepsy Care
- What Comes Next for Genetic Epilepsy Research
- Conclusion
- Frequently Asked Questions
What Makes These Epilepsy Drug Approvals a Breakthrough for Patients With Rare Genetic Conditions?
For decades, treatment for rare genetic epilepsies like Dravet syndrome meant cycling through the same anticonvulsant medications used for more common forms of epilepsy, often with marginal benefit and significant side effects. What separates the current wave of therapies is specificity. Zorevunersen does not simply dampen neural activity across the board. Dravet syndrome is caused by a faulty SCN1A gene that fails to produce enough protein for proper nerve cell signaling. Zorevunersen works by increasing protein production from the patient’s healthy copy of that gene, essentially compensating for what the mutation takes away. That is a fundamentally different approach than anything previously available for this population. The clinical difference is measurable.
In the Phase 1/2a trial of 81 children aged 2 to 18, patients receiving 70 mg of zorevunersen followed by extension doses of up to 45 mg showed median convulsive-seizure frequency reductions ranging from 58.82 percent to 90.91 percent across one-month intervals during the first 20 months. By comparison, many existing antiseizure medications achieve reductions of 20 to 40 percent in this population and are considered successful if they do that much. The gap between those numbers is not academic. It is the difference between a child having multiple seizures a week and going weeks or even months without one. Relutrigine follows a similar precision-medicine logic but targets different genetic variants. As a sodium channel modulator designed for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, it earned FDA Breakthrough Therapy Designation, Orphan drug Designation, and Rare Pediatric Disease Designation, a rare triple distinction that reflects both the severity of the conditions it treats and the strength of early clinical evidence. Its NDA is currently under FDA review.
How Zorevunersen Works and What the Trial Data Reveals
Zorevunersen is administered by lumbar puncture, either as a single dose or as additional doses at two- to three-month intervals over a six-month period. this is not a daily pill. The delivery method matters because the drug needs to reach the central nervous system directly, and lumbar punctures, while routine in pediatric neurology, are not trivial procedures for families. Each dose requires a clinical visit, sedation in many cases for younger children, and a recovery period. Families considering this therapy should understand that the commitment extends well beyond the medication itself. However, the safety profile over the trial period was reassuring. Researchers administered over 800 doses of zorevunersen across the study. The most common side effect was elevated cerebrospinal fluid protein levels, observed in 44 percent of patients in the open-label extension phase.
Critically, none of these elevations were associated with clinical symptoms. No patients withdrew from the trial due to safety concerns related to the drug. Quality-of-life improvements were observed over a three-year period, suggesting the benefits are durable rather than temporary. There is an important caveat. The Phase 1/2a trial enrolled 81 children, which is reasonable for a rare disease study but small by the standards of mainstream drug development. The Phase 3 trial currently enrolling approximately 150 patients across the United States, United Kingdom, and Japan will provide more robust data. Enrollment is expected to complete by the second quarter of 2026, with a data readout targeted for mid-2027 to support a new Drug Application filing. Until that data is in, clinicians and families should view zorevunersen as deeply promising but not yet fully validated at scale.
Relutrigine and the Expanding Landscape of Precision Epilepsy Treatments
Relutrigine, developed by Praxis Precision Medicines, targets a different set of rare genetic epilepsies: those caused by mutations in the SCN2A and SCN8A genes. These developmental and epileptic encephalopathies often present in infancy or early childhood with severe, treatment-resistant seizures and significant developmental delays. Like Dravet syndrome, these conditions have historically been managed with broad-spectrum antiseizure medications that were never designed for the underlying genetic problem. The clinical results from the EMBOLD trial cohort tell a compelling story. Placebo-adjusted seizure reductions reached 46 percent and 53 percent across the two cohorts studied. Those numbers alone would be clinically meaningful, but the open-label extension data at month 11 is where the picture becomes dramatic.
Patients experienced approximately 90 percent seizure reduction, with a mean of 67 seizure-free days compared to just 3 days at baseline. To put that in personal terms, a child who was previously seizing nearly every day was going more than two months without a seizure. Praxis ended its study early specifically because the results were strong enough that continuing to give some patients placebo was no longer ethically justifiable. The NDA was submitted to the fda in early 2026, and an approval decision is pending. If approved, relutrigine would join a very short list of therapies designed from the ground up for genetically defined epilepsies. Families should note, however, that the SCN2A and SCN8A mutations come in different forms, some causing gain of function and others causing loss of function, and not all patients with these mutations will necessarily respond the same way. Genetic testing and careful phenotyping will be essential to identifying who is most likely to benefit.
Ztalmy for CDKL5 Deficiency Disorder — What Families Should Know
Ztalmy, the brand name for ganaxolone, is already FDA-approved for seizures associated with CDKL5 deficiency disorder in patients two years of age and older. CDD is estimated to occur in roughly 1 in 40,000 to 60,000 live births, making it one of the more common genetic forms of epilepsy, though “common” is relative when discussing rare diseases. Its approval was based on a double-blind, randomized, placebo-controlled study in participants aged 2 to 19, the gold standard of clinical trial design. Compared to zorevunersen and relutrigine, Ztalmy represents a different therapeutic approach. It is a neuroactive steroid that modulates GABA-A receptors rather than targeting the specific genetic mechanism of CDD. This means it is treating the seizures rather than the underlying cause, which is an important distinction.
For some families, the practical tradeoff is straightforward: Ztalmy is available now, it is an oral suspension rather than a lumbar puncture, and it has a demonstrated safety profile from controlled trials. But it is not a disease-modifying therapy in the way zorevunersen aims to be. The comparison between these therapies underscores a broader tension in rare disease treatment. Disease-modifying therapies like zorevunersen offer the potential for more fundamental improvement, but they are newer, more invasive to administer, and in many cases not yet approved. Symptomatic treatments like ganaxolone are accessible today and meaningful for patients who need help now. Families navigating these decisions should work closely with pediatric neurologists who specialize in genetic epilepsies, because the right choice depends heavily on the specific diagnosis, the severity of seizures, and the child’s overall clinical picture.
Challenges and Limitations in Rare Genetic Epilepsy Treatment
The enthusiasm surrounding these breakthroughs should be tempered by some practical realities. First, access is a significant concern. Treatments for rare genetic conditions are almost invariably expensive, and insurance coverage can be inconsistent. Ztalmy, for example, carries a list price that puts it out of reach for many families without robust insurance or patient assistance programs. Zorevunersen and relutrigine, if approved, will likely face similar pricing pressures given the small patient populations and high development costs. Second, diagnosis remains a bottleneck. Many children with rare genetic epilepsies go years before receiving a correct diagnosis.
Dravet syndrome is frequently misdiagnosed as febrile seizures or generalized epilepsy in infancy, and SCN2A and SCN8A mutations require genetic testing that is not universally available or routinely ordered. A precision therapy is only useful if the patient’s condition has been precisely identified. Advocacy organizations and clinical geneticists have pushed for broader genetic testing in children with early-onset, treatment-resistant epilepsy, but the infrastructure is uneven, particularly outside major academic medical centers. Third, long-term data is limited. The zorevunersen quality-of-life improvements observed over three years are encouraging, but three years is a short window for a condition that lasts a lifetime. Whether these treatments maintain their efficacy over decades, whether resistance develops, and what the cumulative effects of repeated lumbar punctures or long-term sodium channel modulation look like are questions that cannot yet be answered. Families should approach these therapies with informed optimism rather than the expectation that a single drug will resolve all aspects of their child’s condition.
The Role of Genetic Testing in Unlocking Precision Epilepsy Care
The common thread linking zorevunersen, relutrigine, and ganaxolone is that each targets a genetically defined condition. Without knowing the specific mutation, a clinician cannot match a patient to the right precision therapy. Consider a child diagnosed broadly with “epileptic encephalopathy” who has failed multiple standard anticonvulsants. If that child carries an SCN2A gain-of-function mutation, relutrigine could be transformative.
If the child has a CDKL5 mutation, Ztalmy is already available. But without genetic testing, both options remain invisible. Whole-exome sequencing and targeted epilepsy gene panels have become more accessible in recent years, and some insurers now cover them for children with treatment-resistant seizures. Families who have not pursued genetic testing should discuss it with their neurologist, particularly if seizures began in the first two years of life, if standard medications have been ineffective, or if there are developmental delays alongside the epilepsy. The results may open doors to therapies that were not previously on the table.
What Comes Next for Genetic Epilepsy Research
The pipeline for genetically targeted epilepsy therapies is deeper than it has ever been. The zorevunersen Phase 3 trial, enrolling roughly 150 patients across three countries, will be the definitive test of whether the dramatic early results hold up in a larger, more diverse population. Data is expected by mid-2027. If relutrigine receives FDA approval, it will validate the commercial viability of precision therapies for rare pediatric epilepsies, potentially encouraging investment in treatments for other genetic epilepsy subtypes that currently have nothing in development.
Beyond these specific drugs, the approach itself is what matters most. The idea that you can identify a broken gene, understand the molecular consequence, and design a therapy to correct or compensate for that specific defect is no longer theoretical. It is producing 90 percent seizure reductions in children who previously had almost no seizure-free days. For the broader brain health and neurology community, these rare disease programs serve as proof of concept for precision neurology, an approach that may eventually extend to more common neurological conditions where genetic contributors are becoming better understood.
Conclusion
The approval and development of genetically targeted epilepsy drugs marks a genuine turning point for patients with rare conditions like Dravet syndrome, SCN2A/SCN8A developmental and epileptic encephalopathies, and CDKL5 deficiency disorder. Zorevunersen’s up to 91 percent seizure reduction, relutrigine’s 67 seizure-free days versus 3 at baseline, and Ztalmy’s established efficacy in CDD represent three distinct but converging paths toward precision treatment. These are not incremental improvements over existing medications.
They are fundamentally different therapies built on an understanding of the specific genetic defects driving each condition. For families affected by these rare epilepsies, the practical next steps are clear: pursue genetic testing if it has not been done, connect with a pediatric epilepsy specialist at a center involved in clinical trials, and stay informed about the Phase 3 zorevunersen data expected in 2027 and the FDA’s pending decision on relutrigine. No single therapy will be right for every patient, and access and cost barriers remain real obstacles. But for the first time, the question for many of these families is shifting from “Is there anything that can help?” to “Which of these options is the best fit for my child?”.
Frequently Asked Questions
What is Dravet syndrome?
Dravet syndrome is a rare genetic epilepsy caused by mutations in the SCN1A gene. It typically begins in the first year of life and causes frequent, severe seizures that are resistant to most standard antiseizure medications. It also often involves developmental delays, movement difficulties, and other neurological challenges.
How is zorevunersen administered?
Zorevunersen is given by lumbar puncture, either as a single dose or with additional doses at two- to three-month intervals over a six-month period. It is not an oral medication. Each administration requires a clinical visit and, in many pediatric cases, sedation.
Is Ztalmy (ganaxolone) available now?
Yes. Ztalmy is FDA-approved for seizures associated with CDKL5 deficiency disorder in patients two years of age and older. It is an oral suspension, making it more straightforward to administer than treatments requiring lumbar puncture.
How do I find out if my child has a genetic form of epilepsy?
Genetic testing, including epilepsy gene panels or whole-exome sequencing, can identify mutations in genes like SCN1A, SCN2A, SCN8A, and CDKL5. Discuss testing with a pediatric neurologist, especially if seizures began early in life, are resistant to treatment, or are accompanied by developmental delays.
When will zorevunersen be available to patients outside of clinical trials?
The Phase 3 trial is expected to complete enrollment by mid-2026, with results anticipated around mid-2027. If the data supports approval, a New Drug Application would follow. Realistically, broad availability is likely still two or more years away, though expanded access programs may become available sooner.
What are SCN2A and SCN8A developmental and epileptic encephalopathies?
These are severe epilepsy syndromes caused by mutations in the SCN2A or SCN8A genes, which affect sodium channels in the brain. They typically present in infancy or early childhood with frequent seizures and significant developmental impairment. Relutrigine, currently under FDA review, is the first therapy specifically designed for these conditions.
